SCIENTIFIC ADVISORY BOARD
John M. Amatruda, MD
Dr. Amatruda has broad clinical development expertise in metabolic disease. Most recently, he was Senior Vice President and Franchise Head for Diabetes and Obesity at Merck. Dr. Amatruda oversaw the development and commercialization of Januvia® and Janumet® for the treatment of diabetes, which had combined sales of more than $3 billion in 2010. He led Merck's drug discovery and development groups in Obesity and Diabetes and development groups in Atherosclerosis and Cardiovascular Disease. Prior to that, Dr. Amatruda created and managed a Metabolism drug discovery group at Bayer Corporation as Vice President of Metabolic Disorders Research. Before joining industry, he was a Professor of Medicine Adjunct at Yale University School of Medicine and a Professor of Medicine at the University of Rochester School of Medicine, where he was also head of the Clinical Research Center and acting Head of the Endocrine Metabolism Unit. He is board-certified in Internal Medicine and in Endocrinology and Metabolism and continues to see patients. He received a BS from Yale University and an MD from the Medical College of Wisconsin. He completed his training in Internal Medicine and in Endocrinology and Metabolism at The Johns Hopkins Hospital.
Michael C. Camilleri, MD
Dr. Camilleri is a Professor of Medicine and Physiology in the Mayo Clinic College of Medicine. He is a leading expert in gastroenterology, with a research focus on enteric neurosciences and the physiology, pathophysiology, and treatment of diseases that affect gastrointestinal motility, including gastroparesis, diabetes, obesity, and irritable bowel syndrome. Dr. Camilleri is an author of more than 300 publications that focus on the development of new treatments and diagnostic tools for disordered gut function, obesity, and the problems of diabetes. His awards include the Mayo Clinic Department of Internal Medicine's Outstanding Investigator Award, the Janssen Research Foundation Clinical Research Award, and the Functional Brain-Gut Research Scientist Award. He received his undergraduate training and medical degree from the University of Malta and his academic and clinical training at Hammersmith Hospital and the Royal Postgraduate Medical School in London. Dr. Camilleri received a Masters degree from the University of London and is an elected member of the Fellowship of the Royal Colleges of Physicians of London and Edinburgh.
William W. Chin, MD
Dr. Chin is Executive Dean for Research at Harvard Medical School (HMS), following a 10-year career at Eli Lilly and Company, where he was most recently Senior Vice President for Discovery Research and Clinical Investigation. Prior to Lilly, Dr. Chin was a Professor of Medicine and a Professor of Obstetrics, Gynecology, and Reproductive Biology at Harvard Medical School. Previously, he was an Investigator of the Howard Hughes Medical Institute and served as Chief of the Division of Genetics and as a Senior Physician at the Brigham and Women's Hospital. As a molecular endocrinologist, he pioneered the understanding of the molecular mechanisms of nuclear receptor action with a focus on thyroid, estrogen, and other hormones, as well as various aspects of hormonal regulation of pituitary hormone gene expression. He is a recipient of The Endocrine Society's Robert H. Williams Distinguished Leadership Award, the Sidney H. Ingbar and Van Meter Awards bestowed by the American Thyroid Association, the Bowditch Award from the American Physiological Society, and the AFCR Young Investigator Award; and he is an elected member of the American Society for Clinical Investigation and the American Association of Physicians. Dr. Chin is an overseer of the New England Conservatory of Music and a co-chair of Project Success, a science program for underprivileged secondary students in Boston. He received an AB in Chemistry summa cum laude from Columbia College and a medical degree from Harvard Medical School. He completed a Residency in Internal Medicine at the Beth Israel Hospital and a Fellowship in Endocrinology and Metabolism at the Massachusetts General Hospital.
Lee M. Kaplan, MD, PhD
| Chair of the SAB
Dr. Kaplan is Director of the Obesity, Metabolism, & Nutrition Institute and was Founding Director of the Weight Center at the Massachusetts General Hospital (MGH). He is an Associate Professor of Medicine at Harvard Medical School. He is Director of the recently established Training Program in Obesity Medicine and Nutrition at MGH, Associate Director of the NIH-funded Boston-area Obesity and Nutrition Research Center, Chairman of the Advisory Council of the Washington, DC-based Campaign to End Obesity, a member of the NIH Clinical Obesity Research Panel, and Vice Chair of the Nutrition and Obesity Section of the American Gastroenterological Association. Dr. Kaplan's clinical expertise is in the areas of obesity medicine, gastroenterology, and liver disease. The author of more than 150 medical and scientific papers, he has a special interest in the causes and complications of obesity and the development of new and more effective preventive strategies and therapies for this problem. His clinical research is focused on identifying clinically relevant subtypes of obesity and exploring novel, combinatorial approaches to the treatment of obesity and its complications. Dr. Kaplan's basic research is focused on the physiological and molecular mechanisms of gastrointestinal regulation of body weight and metabolic function, and his group has developed and used several rodent models of weight-loss surgery and gastrointestinal devices to explore these issues. Dr. Kaplan graduated with honors from Harvard University. He received his MD and PhD in Molecular Biology, both with distinction, from the Albert Einstein College of Medicine. He completed an Internship and Residency in Internal Medicine and a Fellowship in Gastroenterology at the Massachusetts General Hospital and Harvard Medical School.